EUVIMEDEUVIMED entdecken
Vergleichsstudie

Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing

Apinya Boonpeng, Sutep Jaruratanasirikul, Monchana Jullangkoon, Maseetoh Samaeng

European Journal of Clinical Pharmacology · 2026-07 · 82 (7)

DOI: 10.1007/s00228-026-04096-6 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 11.06.2026. Verfasst von Apinya Boonpeng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000, Thailand. apinya.bo@up.ac.th. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Imipenem, Models, Biological, Cilastatin, Imipenem Drug Combination. Die Arbeit nennt 27 Literaturangaben. Gefördert von: the Thailand Science Research and Innovation Fund, the University of Phayao, Graduate School, Prince of Songkla University, Thailand, Faculty of Medicine,Prince of Songkla University, Thailand..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Optimizing imipenem therapy in intensive care patients presents challenges due to pathophysiological changes affecting drug disposition. This study developed a population pharmacokinetics model, determined optimal dosing strategies, and described the observed pharmacokinetic/pharmacodynamic (PK/PD) target attainment and clinical outcomes. METHODS: Critically ill patients receiving imipenem/cilastatin were enrolled prospectively. Five blood samples per patient were collected within 24-48 h of treatment initiation. Nonlinear mixed-effects modeling characterized drug pharmacokinetics, with Monte Carlo simulations assessing target attainment probabilities. RESULTS: The study enrolled 21 critically ill patients. A two-compartment model with first-order elimination optimally described imipenem pharmacokinetics, with estimated parameters including total clearance (8.75 L/h), intercompartmental clearance (15.9 L/h), central volume (15.2 L), and peripheral volume (23.4 L). Among evaluated covariates, only estimated glomerular filtration rate (using CKD-EPI 2021 equation) significantly influenced drug clearance. Probability of target attainment analysis (PTA) demonstrated that conventional dosing regimens provided ≥ 90% probability of achieving 40% free time above MIC (fT > MIC) for organisms with MIC values ≤ 2 mg/L. Achieving 75% fT > MIC required maximum conventional doses, whereas 100% fT > MIC with adequate PTA (≥ 80%) necessitated continuous infusion strategies employing doses 30-50% above standard recommendations. Clinical success was observed in 23% of patients (3/13), with higher fT > MIC values among successful cases. However, treatment failure still occurred in some patients despite achieving 100% fT > MIC, suggesting multifactorial determinants of outcomes in critically ill patients. CONCLUSION: Renal function significantly influences imipenem clearance. While standard dosing provides sufficient coverage for conventional PK/PD targets, continuous infusions should be considered for more aggressive targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsImipenemModels, BiologicalCilastatin, Imipenem Drug CombinationHumansCritical IllnessFemaleMaleMiddle AgedAgedProspective StudiesGlomerular Filtration RateMonte Carlo MethodMicrobial Sensitivity TestsAdult

Stichwörter der Autor:innen

ImipenemOutcomesPopulation pharmacokineticsTarget attainment

Substanzen

Anti-Bacterial AgentsImipenemCilastatin, Imipenem Drug Combination

Autor:innen und Institutionen

  • Division of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, 56000, Thailand. apinya.bo@up.ac.th.
  • Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, 90110, Thailand.

Förderung

  • the Thailand Science Research and Innovation Fund, the University of Phayao
  • Graduate School, Prince of Songkla University, Thailand
  • Faculty of Medicine,Prince of Songkla University, Thailand.

Zitieren

APA

Boonpeng, A., Jaruratanasirikul, S., Jullangkoon, M., & Samaeng, M. (2026). Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing. European Journal of Clinical Pharmacology, 82(7). https://doi.org/10.1007/s00228-026-04096-6

Vancouver

Boonpeng A, Jaruratanasirikul S, Jullangkoon M, Samaeng M. Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing. European Journal of Clinical Pharmacology. 2026;82(7). doi:10.1007/s00228-026-04096-6

BibTeX
@article{Boonpeng2026,
  author = {Boonpeng, Apinya and Jaruratanasirikul, Sutep and Jullangkoon, Monchana and Samaeng, Maseetoh},
  title = {Population pharmacokinetics of unbound imipenem in critically ill patients: a comparison of five renal function estimators for PK/PD-guided dosing},
  journal = {European Journal of Clinical Pharmacology},
  year = {2026},
  volume = {82},
  number = {7},
  doi = {10.1007/s00228-026-04096-6}
}
Kostenlos starten →